BioHarvest Sciences
Makes plant-cell compounds for VINIA and CDMO partners.
Something off on this page? Send us feedback.
Profile
Uses plant-cell cultivation to make plant-based compounds without growing the underlying plant. Its Products business sells VINIA, while CDMO Services applies the same Botanical Synthesis platform for industry partners.
Botanical Synthesis grows plant cells to develop plant-based compounds without cultivating the source plant. The platform supports proprietary direct-to-consumer products and CDMO Services for industry partners.
VINIA, a red-grape-cell polyphenol nutraceutical, is the first proprietary commercial product. CDMO Services extends the same process to pharmaceutical, nutraceutical, cosmeceutical, and nutrition applications.
Founded in Israel in 2007, the operating business is paired with a Canadian public parent and a Nasdaq listing. Registered in Vancouver with a principal operating base in Rehovot, Israel, operations are led by co-founder and CEO Dr. Zaki Rakib.
The two routes depend on continued product commercialization and the ability to win and execute CDMO development agreements.
Company facts
Key statistics
Year to date −64.9% · Average volume (30d) 69.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 12, 2026 | Maxim Group | Reiterate | Buy | $12 | $5 |
| Feb 19, 2026 | Roth Capital | Target | $10 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.13 | −$0.17 | −30.8% | $9.5M | $8.8M | −6.5% | −0.95% |
| May 14, 2026Q1 FY26 | −$0.13 | −$0.11 | +15.4% | $8.5M | $8.5M | +0.1% | −1.44% |
| Mar 31, 2026Q4 FY25 | −$0.11 | −$0.10 | +4.8% | $9.2M | $9.1M | −1.5% | −0.69% |
| Nov 13, 2025Q3 FY25 | −$0.14 | −$0.14 | 0.0% | $9.2M | $9.1M | −1.0% | −0.96% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $7.9M | $8.5M | $9.1M | $9.1M | $8.5M | $8.8M | |
| Gross profit | $4.6M | $5.1M | $5.6M | $5.2M | $5.0M | $5.1M | |
| Operating income | −$1.7M | −$1.8M | −$920.0K | −$1.1M | −$1.8M | −$2.5M | |
| Net income | −$2.3M | −$4.1M | −$2.5M | −$2.2M | −$2.6M | −$3.7M | |
| Diluted EPS | −$0.13 | −$0.24 | −$0.14 | −$0.12 | −$0.12 | −$0.16 | |
| Gross margin | 58.5% | 59.7% | 61.4% | 57.6% | 59.2% | 57.5% | |
| Operating margin | -21.9% | -21.3% | -10.1% | -12.4% | -21.6% | -28.4% |
Fiscal years (4-quarter sums)FY21 $2.1M · FY22 $5.5M · FY23 $12.7M · FY24 $25.2M · FY25 $34.5M
Revenue by product · FY25
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $16.2M · Total debt $17.5M · Total assets $44.6M · Shareholders' equity $19.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 17.33M · Float 14.53M · 83.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 581.4K | 3.36% | 13F | Aug 14, 2026 |
| Thompson Siegel & Walmsley LLC | 364.0K | 2.10% | 13F | Aug 11, 2026 |
| Evercore Wealth Management, LLC | 216.3K | 1.25% | 13F | Aug 14, 2026 |
| True North Advisors, LLC | 187.3K | 1.08% | 13F | Jul 22, 2026 |
| Magnus Financial Group LLC | 90.0K | 0.52% | 13F | Jul 9, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Niagen Bioscience
Science-backed healthy-aging supplements led by Tru Niagen
- LifeVantage
Direct-selling wellness supplements led by Protandim
- Natural Alternatives International
Private-label nutritional-supplement formulation and manufacturing
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioHarvest Sciences | $1.84 | +0.55% | $31.9M | — | — | 0.9 | +3.8% |
| Niagen Bioscience | $3.30 | +0.15% | $262.0M | 17.7 | 29.5 | 2.0 | −4.3% |
| LifeVantage | $6.26 | −1.11% | $80.2M | 15.9 | 17.3 | 0.4 | −23.1% |
| Natural Alternatives International | $2.16 | −2.26% | $13.6M | — | — | 0.1 | +22.7% |
| Median | 16.8 | 23.4 | 0.4 | −4.3% |